Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Enrich

Otolaryngology Nashville, TN Medical Doctor

NPI 1689858201 CMS profile 258346

3443 Dickerson Pike Ste 320, Nashville, TN 37207

Open in the dashboard

General payments

$11,324

156 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Enrich of Nashville, TN is reported in the CMS Open Payments database as having received $11,324 across 156 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $486 9
2024 General $236 4
2023 General $366 10
2022 General $2,652 38
2021 General $2,324 35
2020 General $1,102 20
2019 General $4,158 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Enrich
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Steven Enrich were reported at $486. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Steven Enrich Otolaryngology median Middle half National median
2019 $4,158 $194 $82–$512 $163
2020 $1,102 $118 $42–$280 $114
2021 $2,324 $167 $63–$444 $132
2022 $2,652 $216 $84–$545 $149
2023 $366 $235 $93–$588 $160
2024 $236 $280 $111–$699 $164
2025 $486 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $6,661 91 payments
  2. Intersect ENT, Inc. $3,087 13 payments
  3. Acclarent, Inc $412 10 payments
  4. Aerin Medical Inc. $398 9 payments
  5. Olympus America Inc. $197 5 payments
  6. ALK-Abello, Inc $90 4 payments
  7. GlaxoSmithKline, LLC. $80 5 payments
  8. Novartis Pharmaceuticals Corporation $58 3 payments
  9. Genzyme Corporation $58 3 payments
  10. OptiNose US, Inc. $48 3 payments
  11. Other $233 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,339 149 payments
  2. Travel and Lodging $2,985 7 payments
Products named General payments · program years 2019–2025
  1. PROPEL $3,072 12 payments
  2. SINUVA $2,760 6 payments
  3. XPRESS ENT DILATION SYSTEM $1,961 28 payments
  4. FIAGON NAVIGATION UNIT $877 6 payments
  5. MEDLINE INDUSTRIES, INC. $774 11 payments
  6. ENTELLUS - XPRESS ENT DILATION SYSTEM $586 11 payments
  7. CLARIFIX CRYOTHERAPY DEVICE $557 5 payments
  8. ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM $507 7 payments
  9. CMI $370 4 payments
  10. ENTELLUS - OFFICE SINUS PROCEDURE PACK $322 3 payments
  11. Other $3,218 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

515

Median for Otolaryngology: 297

Drug cost

$11,585

Median for Otolaryngology: $6,314

Branded share of claims

14.4%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mometasone Furoate Generic 47 $5,033
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 17 $1,629
Ipratropium Bromide Generic 46 $1,243
Omeprazole Generic 126 $1,015
Azelastine Hcl Generic 21 $467
Cefdinir Generic 16 $350
Esomeprazole Magnesium Generic 12 $300
Levocetirizine Dihydrochloride Generic 20 $288
Doxycycline Hyclate Generic 31 $272
Mupirocin Generic 41 $249

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$86,587

Medicare's payments for the services billed

Medicare patients

197

Average age 74

Services billed

1,496

109 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 35%
Diabetes 31%
Chronic kidney disease 31%
Depression 22%
COPD 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record